Limb-Girdle Muscular Dystrophy clinical trials at UC Irvine

3 in progress, 2 open to eligible people

Showing trials for

  • AB-1003 (Previously LION-101) in Subjects With Genetic Confirmation of LGMD2I/R9 (Part1)

    open to eligible people ages 18-65

    The purpose of this study is to evaluate the safety and tolerability of a single intravenous infusion of AB-1003 in adults diagnosed with limb girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). Participants will be treated in sequential, dose-level cohorts. (Part 1)

    Irvine, California and other locations

  • LGMD R1 Natural History Study

    open to eligible people ages 12-50

    This is a 24-month, observational study of 100 participants with Limb Girdle Muscular Dystrophy type R1, also known as CAPN3.

    Orange, California and other locations

  • BBP-418 (Ribitol) in Patients With Limb Girdle Muscular Dystrophy 2I (LGMD2I)

    Sorry, in progress, not accepting new patients

    This study will evaluate the safety and efficacy of long-term administration of BBP-418 in patients with LGMD2I/R9. The study will include patients ages 12 to 60, consistent with the existing preclinical toxicology profile. This will encompass the significant majority of existing diagnosed patients based upon the established epidemiology of the disease.

    Irvine, California and other locations

Our lead scientists for Limb-Girdle Muscular Dystrophy research studies include .

Last updated: